trans-farnesylthiosalicylic acid
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2006 (NCT00867230)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transforming protein p21/H-Ras-1INHIBITOR
HRAS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- trans-farnesylthiosalicylic acid
- trans-farnesylthiosalicylic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00867230 | Phase 1 | May 1, 2006 | Advanz Pharma, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advanz Pharma | For profit | 1 | 0 | 1 | 2006 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2006 |
2 organizations
Page 1 / 1